Quinupristin/dalfopristin: a therapeutic review (Q28202172)

Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal

Europe PubMed Central

title

Quinupristin/dalfopristin: a therapeutic review (English)

0 references

author name string

D R Allington

series ordinal

1

0 references

M P Rivey

series ordinal

2

0 references

language of work or name

English

0 references

publication date

January 2001

0 references

published in

Clinical Therapeutics

0 references

volume

23

0 references

issue

1

0 references

page(s)

24-44

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

A novel antimicrobial agent joins the battle against resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

An overview of nosocomial infections, including the role of the microbiology laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Methicillin-resistant Staphylococcus aureus: long-term care concerns

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Costs of treating infections caused by methicillin-resistant staphylococci and vancomycin-resistant enterococci

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Gram-positive resistance: challenge for the development of new antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Streptogramins: an answer to antibiotic resistance in gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Current and future management of infections due to methicillin-resistant staphylococci infections: the role of quinupristin/dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Optimal treatment of complicated skin and skin structure infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Occurrence and epidemiology of resistance to virginiamycin and streptogramins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Pharmacokinetics of quinupristin-dalfopristin in continuous ambulatory peritoneal dialysis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Prevalence of resistance to MLS antibiotics in 20 European university hospitals participating in the European SENTRY surveillance programme. Sentry Participants Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Quinupristin/dalfopristin: therapeutic potential for vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Antipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Activity of quinupristin/dalfopristin and its components against Haemophilus influenzae

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Postantibiotic effect and postantibiotic sub-MIC effect of quinupristin-dalfopristin against gram-positive and -negative organisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infect

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021

Safety and tolerability of quinupristin/dalfopristin: administration guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980028-X

7 January 2021